Arbutus Biopharma Corporation (ABUS)

NMS – Цена в реальном времени. Валюта: USD

4.58

+0.17 (3.85%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

4.65

+0.07 (1.53%)

После закрытия: Jun 26, 2026, 6:14 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Arbutus Biopharma Corporation (ABUS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Arbutus Biopharma Corporation (ABUS)

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts

Видео

No Data

Пресс-релизы

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Search stocks

Arbutus Biopharma Corporation (ABUS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Arbutus Biopharma Corporation (ABUS)

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts

Видео

No Data

Пресс-релизы

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna